Immune Response to the PASD1 Protein in Malaysian Patients with Haematological Malignancies
By: Hanif Zulkhairi Mohamad Said (h.zulkh@gmail.com)
Tumor-associated antigens recognized by the immune system of cancer patients may represent not only biomarkers for improved diagnosis and/or prognosis but also targets for improved treatment options for these patients. Such molecules are of particular importance in lymphomas such as Diffuse Large B Cell Lymphoma (DLBCL), Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and T/NK cell Lymphomas where a significant number of patients die of their disease.
The aim of this study is to focus primarily upon the further investigation of immunotherapeutic targets for DLBCL, MCL, MM, and T/NK cell lymphomas, where the major area of investigation is on further characterization and validation of the novel Cancer Testis Antigen (CTA) PASD1 as an immunotherapeutic target in haematological malignancies.
Other CTAs identified previously by the Lymphoma Research Group in Oxford as being of potential importance is explored with the aim of identifying additional candidates for the development of a lymphoma vaccine. Work is carried out to obtain information on the relevance of these lymphoma-associated antigens to assess their potential as diagnostic/prognostic markers in DLBCL and other leukaemias/lymphomas.
Our aim is to validate the previous findings by the Lymphoma Research Group in Oxford on the PASD1 proteins as potential vaccine candidates in Malaysian patients with various haematological malignancies.
